Hikma Pharmaceuticals PLC (LSE:HIK) — Stock Price

GBX1649.00 GBX
▼ -1.67% today

Hikma Pharmaceuticals PLC (LSE:HIK) is currently trading at GBX1649.00 GBX, down 1.67% today. Over the past 52 weeks, shares have ranged between GBX1191.00 and GBX1851.00. This page tracks Hikma Pharmaceuticals PLC's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see HIK stock market capitalisation.

Hikma Pharmaceuticals PLC (HIK) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Hikma Pharmaceuticals PLC's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.

Hikma Pharmaceuticals PLC Income Statement — Revenue, Profit & Earnings by Year

Hikma Pharmaceuticals PLC's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023202220212020
Total Revenue GBX3.13 Billion GBX2.88 Billion GBX2.52 Billion GBX2.55 Billion GBX2.34 Billion
Cost of Revenue GBX1.71 Billion GBX1.47 Billion GBX1.25 Billion GBX1.25 Billion GBX1.13 Billion
Gross Profit GBX1.42 Billion GBX1.41 Billion GBX1.26 Billion GBX1.30 Billion GBX1.21 Billion
Research & Development GBX141.00 Million GBX149.00 Million GBX144.00 Million GBX143.00 Million GBX137.00 Million
SG&A GBX568.00 Million GBX638.00 Million GBX509.00 Million GBX488.00 Million GBX464.00 Million
Total Operating Expenses GBX803.00 Million GBX1.04 Billion GBX976.00 Million GBX715.00 Million GBX621.00 Million
Operating Income GBX612.00 Million GBX367.00 Million GBX591.00 Million GBX634.00 Million GBX540.00 Million
EBITDA GBX787.00 Million GBX791.00 Million GBX485.00 Million GBX744.00 Million GBX631.00 Million
EBIT GBX608.00 Million GBX619.00 Million GBX292.00 Million GBX600.00 Million GBX540.00 Million
Interest Expense GBX75.00 Million GBX90.00 Million GBX77.00 Million GBX40.72 Million GBX56.00 Million
Income Before Tax GBX455.00 Million GBX281.00 Million GBX233.00 Million GBX544.00 Million GBX558.00 Million
Income Tax Expense GBX93.00 Million GBX89.00 Million GBX42.00 Million GBX124.00 Million GBX128.00 Million
Net Income GBX359.00 Million GBX190.00 Million GBX188.00 Million GBX421.00 Million GBX431.00 Million

Hikma Pharmaceuticals PLC Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Hikma Pharmaceuticals PLC's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023202220212020
Total Assets GBX5.13 Billion GBX4.68 Billion GBX4.47 Billion GBX4.37 Billion GBX4.13 Billion
Total Current Assets GBX2.26 Billion GBX2.10 Billion GBX2.00 Billion GBX2.09 Billion GBX1.92 Billion
Cash & Equivalents — — — — —
Short-term Investments GBX25.00 Million GBX24.00 Million GBX22.00 Million GBX24.00 Million GBX24.00 Million
Net Receivables GBX905.00 Million GBX789.00 Million GBX777.00 Million GBX781.00 Million GBX662.00 Million
Inventory GBX986.00 Million GBX891.00 Million GBX776.00 Million GBX695.00 Million GBX757.00 Million
Property, Plant & Equipment — — GBX1.08 Billion GBX1.15 Billion GBX1.07 Billion
Goodwill GBX382.00 Million GBX388.00 Million GBX389.00 Million GBX285.00 Million GBX289.00 Million
Total Liabilities GBX2.81 Billion GBX2.47 Billion GBX2.32 Billion GBX1.91 Billion GBX1.99 Billion
Total Current Liabilities GBX1.98 Billion GBX1.34 Billion GBX1.08 Billion GBX1.02 Billion GBX1.03 Billion
Long-term Debt GBX607.00 Million GBX975.00 Million GBX1.07 Billion GBX651.00 Million GBX692.00 Million
Net Debt GBX1.12 Billion GBX986.00 Million GBX1.01 Billion GBX420.00 Million GBX609.00 Million
Total Stockholder Equity GBX2.31 Billion GBX2.20 Billion GBX2.13 Billion GBX2.45 Billion GBX2.13 Billion
Retained Earnings GBX2.36 Billion GBX2.16 Billion GBX2.09 Billion GBX2.19 Billion GBX1.89 Billion

Hikma Pharmaceuticals PLC Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Hikma Pharmaceuticals PLC generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023202220212020
Operating Cash Flow GBX564.00 Million GBX608.00 Million GBX530.00 Million GBX638.00 Million GBX464.00 Million
Capital Expenditures GBX165.00 Million GBX169.00 Million GBX225.00 Million GBX229.00 Million GBX224.00 Million
Free Cash Flow GBX399.00 Million GBX439.00 Million GBX305.00 Million GBX409.00 Million GBX240.00 Million
Investing Cash Flow GBX-381.00 Million GBX-333.00 Million GBX-607.00 Million GBX-238.00 Million GBX-283.00 Million
Financing Cash Flow GBX-188.00 Million GBX-337.00 Million GBX-58.00 Million GBX-287.00 Million GBX-298.00 Million
Dividends Paid GBX-175.00 Million GBX-137.00 Million GBX125.00 Million GBX120.00 Million GBX109.00 Million
Stock-Based Compensation GBX27.00 Million GBX25.00 Million GBX22.00 Million GBX29.00 Million GBX27.00 Million
Depreciation GBX197.00 Million GBX190.00 Million GBX193.00 Million GBX145.00 Million GBX91.00 Million
Change in Cash GBX-17.00 Million GBX-65.00 Million GBX-156.00 Million GBX103.00 Million GBX-119.00 Million

Hikma Pharmaceuticals PLC Earnings History — EPS Actual vs. Analyst Estimates

Track Hikma Pharmaceuticals PLC's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Feb 25, 2026 — — —
Aug 07, 2025 1.07 1.21 -11.57%
Apr 25, 2025 — — —
Mar 19, 2025 0.60 0.00 —
Feb 23, 2023 0.00 0.82 -100.00%
Aug 04, 2022 0.00 0.95 -100.00%
Feb 24, 2022 0.00 0.98 -100.00%
Aug 06, 2021 0.00 0.90 -100.00%